[High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)]

Standard

[High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)]. / Janka-Schaub, Gritta; Wiesner, H; Bidlingmaier, F; Haas, R J.

In: Klin Wochenschr, Vol. 57, No. 8, 8, 1979, p. 411-416.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Janka-Schaub, G, Wiesner, H, Bidlingmaier, F & Haas, RJ 1979, '[High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)]', Klin Wochenschr, vol. 57, no. 8, 8, pp. 411-416.

APA

Janka-Schaub, G., Wiesner, H., Bidlingmaier, F., & Haas, R. J. (1979). [High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)]. Klin Wochenschr, 57(8), 411-416. [8].

Vancouver

Janka-Schaub G, Wiesner H, Bidlingmaier F, Haas RJ. [High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)]. Klin Wochenschr. 1979;57(8):411-416. 8.

Bibtex

@article{a20229843de94fe3a21e36ecdc80b32a,
title = "[High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)]",
abstract = "In 22 patients with osteogenic sarcoma, treated with 103 high-dose methotrexate infusions (6-8.5 g/m2 in 4-6 h) plasma methotrexate levels were measured with a specific and rapid radioimmunoassay. Nontoxic infusions were associated with methotrexate concentrations below 8.0 X 10(-6) mol/l at 24 h, 8.0 X 10(-7) mol/l at 48 h and 4.25 X 10(-7)/mol/1 at 72 h. All patients with 48 h methotrexate levels above 1 X 10-6 mol/l manifested severe toxicity with myelosuppression and stomatitis due to delayed methotrexate excretion. Rise of serum creatinine was not reliable to predict oxicity. Determination of 48- and 72-h methotrexate concentrations proved to be a valuable method for identifying patients at high risk for toxic side effects. Additional citrovorum factor may thus be given in time.",
author = "Gritta Janka-Schaub and H Wiesner and F Bidlingmaier and Haas, {R J}",
year = "1979",
language = "Deutsch",
volume = "57",
pages = "411--416",
number = "8",

}

RIS

TY - JOUR

T1 - [High-dose methotrexate therapy in osteogenic sarcoma: plasma pharmakokinetics to predict toxicity (author's transl)]

AU - Janka-Schaub, Gritta

AU - Wiesner, H

AU - Bidlingmaier, F

AU - Haas, R J

PY - 1979

Y1 - 1979

N2 - In 22 patients with osteogenic sarcoma, treated with 103 high-dose methotrexate infusions (6-8.5 g/m2 in 4-6 h) plasma methotrexate levels were measured with a specific and rapid radioimmunoassay. Nontoxic infusions were associated with methotrexate concentrations below 8.0 X 10(-6) mol/l at 24 h, 8.0 X 10(-7) mol/l at 48 h and 4.25 X 10(-7)/mol/1 at 72 h. All patients with 48 h methotrexate levels above 1 X 10-6 mol/l manifested severe toxicity with myelosuppression and stomatitis due to delayed methotrexate excretion. Rise of serum creatinine was not reliable to predict oxicity. Determination of 48- and 72-h methotrexate concentrations proved to be a valuable method for identifying patients at high risk for toxic side effects. Additional citrovorum factor may thus be given in time.

AB - In 22 patients with osteogenic sarcoma, treated with 103 high-dose methotrexate infusions (6-8.5 g/m2 in 4-6 h) plasma methotrexate levels were measured with a specific and rapid radioimmunoassay. Nontoxic infusions were associated with methotrexate concentrations below 8.0 X 10(-6) mol/l at 24 h, 8.0 X 10(-7) mol/l at 48 h and 4.25 X 10(-7)/mol/1 at 72 h. All patients with 48 h methotrexate levels above 1 X 10-6 mol/l manifested severe toxicity with myelosuppression and stomatitis due to delayed methotrexate excretion. Rise of serum creatinine was not reliable to predict oxicity. Determination of 48- and 72-h methotrexate concentrations proved to be a valuable method for identifying patients at high risk for toxic side effects. Additional citrovorum factor may thus be given in time.

M3 - SCORING: Zeitschriftenaufsatz

VL - 57

SP - 411

EP - 416

IS - 8

M1 - 8

ER -